Drugs.com - Clinical Trials

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced...

Jun 26, 2025 - 03:05
 0
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced...
Read More

Tags:

Previous Article

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamt...

Next Article

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Des...

Related Posts

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presented New Data From Pivotal Phase 3 IMPALA-2...

May 26, 2025  0

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Radiopharm Theranostics Granted U.S. Food and Drug Admi...

Jun 26, 2025  0

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Hi...

May 12, 2025  0